Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers

A randomized phase II study in women with metastatic breast cancer who have mutations in BRCA1 or BRCA2 evaluated the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to combination chemotherapy. Although veliparib improved response, the trial did not meet its primary endpoint, according to lead investigator Hyo Sook Han, MD, of the Moffitt Cancer Center in Tampa, Florida. 

 The ASCO Post

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.